Nokia Sensing XCHALLENGE Competition | XPRIZE Foundation

Prize Purse

$2.25 Million

Designed to revolutionize how we detect and manage disease, this prize challenged teams to develop advanced health sensors that can radically improve the accuracy, accessibility, and ease of real-time personal health monitoring.

Impact

$105M+ invested in winning teams to advance health sensing technologies.

6 patents issued to winning teams

3,000+ participants in the world’s largest breath-based clinical trial for early cancer detection

Winner

Nanobiosym (Phase 1) – Developed Gene-RADAR, a portable nanochip device that detects pathogens like HIV or E. coli from a drop of blood or saliva in under an hour, without lab infrastructure.

DNA Medicine Institute (Phase 2) – Created rHealth, a handheld device that runs rapid tests from a single drop of blood, screening for diseases from flu to Ebola, with real-time wireless health data.

Nanobiosym

Boston, United States

Nanobiosym (NBS) is an innovation engine integrating physics, biomedicine, and nanotech to incubate and scale breakthroughs for health, energy, and the environment. Its diagnostics arm, NBSDx, commercializes a proprietary platform that rapidly and accurately detects genetic “fingerprints” from any organism—delivering affordable, portable results at the point of need. The Nanobiosym Global Initiative builds public-private partnerships to deploy these tools worldwide.

DNA Medicine Institute (DMI)

Cambridge, United States

The DNA Medicine Institute, Inc. (DMI) is a medical device company focused on commercializing cutting-edge technologies. DMI is focused on advancing the rHEALTH diagnostic technology, designed to provide multiple lab values off a single drop of blood.